



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 403/00		A2	(11) International Publication Number: WO 99/09025 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/IB98/01198			(81) Designated States: AL, AM, AR, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 5 August 1998 (05.08.98)			
(30) Priority Data: 60/055,764 15 August 1997 (15.08.97) US			
(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).			
(72) Inventors; and			
(73) Inventors/Applicants (for US only): FLIRI, Anton, Franz, Josef [AT/US]; 120 MacKinley Avenue, Norwich, CT 06360-27 (US). MAJCHRZAK, Mark, Jerome [US/US]; 10, Bobwhite Lane, East Lyme, CT 06333 (US). SEYMOUR, Patricia, Ann [US/US]; 23 Broadview Avenue, Uncasville, CT 06382 (US). ZORN, Stevin, Howard [US/US]; P.O. Box 421, North Stonington, CT 06359 (US). ROLLEMA, Hans [NL/US]; 20 Holdridge Court, Mystic, CT 06355 (US).			
(74) Agents: SPIEGEL, Allen, J.; c/o Simpson, Alison, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB) et al.			
(54) Title: 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVE			
<p style="text-align: right;">(I)</p>			
(57) Abstract			
<p>A compound of the formula (I) wherein a, T, V, X, Y, Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined above, their pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds or their salts.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-
1H-INDOLE DERIVATIVES

Background of the Invention

10 The present invention relates to 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives possessing central dopaminergic activity. Such compounds are useful in the treatment of Central Nervous Systems (CNS) disorders. This invention also relates to a method of using such compounds in the treatment of the above disorders in mammals, especially humans, and the pharmaceutical compositions useful therefor.


15 It is generally known that dopamine receptors seem to be important for many functions in the animal body. For example, altered functions of these receptors participate in the genesis of psychosis, drug addiction, compulsive disorders, bipolar disorders, vision, emesis, sleep, feeding, learning, memory, sexual behavior, regulation of immunological responses and blood pressure. Since these receptors control a great 20 number of pharmacological events, not all of them are presently known, there is a possibility that compounds acting preferentially on D4 dopamine receptor may exert a wide range of therapeutic effects in humans.

25 The 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives of the present invention, including forms of tautomers, enantiomers and acceptable acid addition salts, are centrally acting D4-dopamine receptor agonists and thus are useful as cognition enhancers and treatment of CNS diseases, such as Parkinsons disease, Alzheimer's disease, learning and memory abnormalities. Another feature of this invention provides for the use of combinations of compounds of the present invention in conjunction with D1, D2, D3 or D5 dopamine receptor agonists, such as L-dopa and 30 D2 agonists, in treatment of CNS diseases, such as Parkinson's disease, Alzheimer's disease, attention deficit disorder and learning and memory abnormalities.

5

Summary of the Invention

The present invention relates to a compound of the formula



or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

10 a is 0 or 1, wherein when a is 0, X may form an optional double bond with the carbon adjacent to V;

V is CHR^{10} wherein R^{10} is hydrogen or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;

T is nitrogen or CH ;

X is nitrogen or CR^{11} wherein R^{11} is hydrogen, $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$,

15 hydroxy or cyano;

Y and Z are each independently nitrogen or CR^{12} wherein R^{12} is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$ or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;


R^1 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;

20 R^2 , R^6 , R^7 , R^8 and R^9 are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$ and $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;

R^3 and R^4 are each independently hydrogen or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$; and

R^5 is hydrogen, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$, trifluoromethyl, cyano, $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$ or $\text{R}^{13}\text{CO-}$ wherein R^{13} is amino, $(\text{C}_1\text{-}\text{C}_6)\text{alkylamino}$, $((\text{C}_1\text{-}\text{C}_6)\text{alkyl})_2\text{amino}$, $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, $(\text{C}_6\text{-}\text{C}_{10})\text{aryl}$;

25 or when a is 1, R^1 and R^{10} may be taken together with the carbons to which they are attached to form a compound of the formula



5

wherein the broken lines represent optional bonds;

T, X, Y, Z, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are defined as above;

b is 0 or 1; and

A and B are each independently CH, CH₂, oxygen, sulfur, NH or nitrogen;

10 with the proviso that when X is nitrogen, the optional double bond between X and V does not exist;

with the proviso that when b is 0, the optional double bond between A and B does not exist; and

with the proviso that when b is 1, A and B cannot both be oxygen or sulfur.

15 The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is defined above.

20 The term "treating", as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorders or condition. The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.

25 The term "disorders of the dopamine system", as referred to herein, refers to disorders the treatment of which can be effected or facilitated by altering (i.e., increasing or decreasing) dopamine mediated neurotransmission.

The compounds in accordance with the present invention, being ligands for dopamine receptor subtypes, especially the dopamine D₄ receptor, within the body, are accordingly of use in the treatment of disorders of the dopamine system.

30 The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.

5 Preferred compounds of formula I include those wherein X is nitrogen.
Other preferred compounds of formula I include those wherein Y and Z are each CR¹² wherein R¹² is hydrogen or fluoro.
Other preferred compounds of formula I include those wherein R² is hydrogen, fluoro or chloro.

10 Other preferred compounds of formula I include those wherein R³, R⁴ and R⁵ are hydrogen.
Other preferred compounds of formula I include those wherein R⁷ is fluoro or chloro.
Other preferred compounds of formula I include those wherein R⁹ is fluoro, chloro, bromo or alkoxy.

15 More preferred compounds of formula I include those wherein X is nitrogen; Y and Z are each CR¹³ wherein R¹³ is hydrogen or fluoro; R² is hydrogen, fluoro or chloro; R³, R⁴ and R⁵ are hydrogen; R⁷ is fluoro or chloro; and R⁹ is fluoro, chloro, bromo or alkoxy.

20 Specific preferred compounds of formula I include the following:
2-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;
5-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;
5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;
5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;
25 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;
5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole;
30 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole; and
2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-azaindole.

The present invention also relates to a method for treating disorders of the dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La 35 Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and

5 hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

The present invention also relates to a method for treating disorders of the 10 dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal 15 disorders (gastric acid secretion or emesis), chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to formula I, or a pharmaceutically acceptable salt thereof, in conjunction with one or more D1, D2, D3 or D5 dopamine receptor agonists, that is effective in treating 20 such disorder.

The present invention also relates to a pharmaceutical composition for treating disorders of the dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, 25 Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound 30 according to formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

The present invention also relates to a pharmaceutical composition for treating disorders of the dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side 35 effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical abuse, chemical


5 dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to formula I, or a pharmaceutically acceptable salt thereof, in conjunction with one or more D1, D2, D3 or D5 dopamine receptor agonists, that is effective in treating
10 such disorder.

5


Detailed Description of the Invention

The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated a, T, V, X, Y, Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ in the reaction Schemes and the discussion that follow are defined as above.

10

Scheme 1

5

Scheme 2

5 In reaction 1 of Scheme 1, the compounds of formula III and IV are coupled to form the corresponding compound of formula I by first treating III with O-, N- dimethyl hydroxylamine hydrochloride, dicyclohexylcarbodiimide and a base, such as triethylamine, in a polar aprotic solvent, such as methylene chloride. The hydroxamide intermediate so formed is reduced, using a reducing agent such as lithium aluminum 10 hydride, in a polar aprotic solvent, such as tetrahydrofuran. The reductive amination of the aldehyde intermediate so formed is accomplished by reacting the aldehyde with the compound of the formula IV in the presence of sodium triacetoxyborohydride and a polar aprotic solvent, such as dichloroethane. The reaction mixture is stirred, under inert atmosphere, at room temperature for a time period between about 40 hours to 15 about 56 hours, preferably about 48 hours.

15 In reaction 1 of Scheme 2, the compounds of formula VI, wherein L is a leaving group such as chloro, bromo, methoxy or any activated ester derivative such as para-nitro phenyl ester, hydroxy benzotriazole ester, N-hydroxysuccinimide ester or hydroxy, and IV are coupled to form the corresponding methanone compound of formula III by 20 reacting VI and IV in the presence of diisopropylethylamine, carbodiimide or a dehydrating agent and a polar aprotic solvent, such as methylene chloride, or in form of mixtures containing, if desired, combinations of organic solvents or water such as combinations of cyclic and acyclic mono and dialkylamides, (C₁-C₄) alcohols, halogenated solvents, or acyclic and cyclic alkylethers at temperatures ranging from 25 about 0°C to about 150°C, preferably about 0°C or the boiling point of the same solvent mixture. Addition of an acid acceptor such as an alkalicarbonate, a tertiary amine or a similar reagent may be useful.

30 In reaction 2 of Scheme 2, the methanone compound of formula V is converted to the corresponding compound of formula I, wherein R³ and R⁴ are hydrogen, by reducing V with a reducing agent, such as lithium aluminum hydride or a borane derivative, in the presence of a polar aprotic solvent, such as tetrahydrofuran, for a time period between about 10 hours to about 14 hours, preferably about 12 hours.

35 In each of the above reactions, pressure is not critical. Pressures in the range of about 0.5 atmospheres to 3 atmospheres are suitable, and ambient pressure (generally, about one atmosphere) is preferred as a matter of convenience. Also, for those reactions where the preferred temperature varies with the particular compounds reacted, no preferred temperature is stated. For such reactions, preferred

5 temperatures for particular reactants may be determined by monitoring the reaction using thin layer chromatography.

The novel compounds of the formula I and the pharmaceutically acceptable salts thereof (herein "the therapeutic compounds of this invention") are useful as dopaminergic agents, i.e., they possess the ability to alter dopamine mediated neurotransmission in 10 mammals, including humans. They are therefore able to function as therapeutic agents in the treatment of a variety of conditions in mammals, the treatment or prevention of which can be effected or facilitated by an increase or decrease in dopamine mediated neurotransmission.

The compounds of the formula I that are basic in nature are capable of forming a 15 wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter 20 free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The 25 desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.

The therapeutic compounds of this invention can be administered orally, transdermally (e.g. through the use of a patch), parenterally or topically. Oral administration is preferred. In general, these compounds are most desirably administered 30 in dosages ranging from about 0.1 mg up to about 1000 mg per day, or 1 mg to 1000 mg per day in some cases, although variations may occur depending on the weight and condition of the person being treated and the particular route of administration chosen. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing 35 any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

5 The therapeutic compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the two routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic compounds of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined
10 with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, for example. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or
15 flavored.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with
20 granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When
25 aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

30 For parenteral administration, solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intra-articular, intramuscular and
35 subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

5 Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

10 The ability of compounds to bind to mammalian dopamine receptors, and the relative ability of compounds of this invention to inhibit [³H]-spiperone binding to human dopamine D₄ receptor subtypes expressed in clonal cell lines was measured using the following procedure.

D₄ Receptor Binding Ability

15 The determination of D₄ receptor binding ability has been described by Van Tol, et al. (*Nature*, 1991, 350, 610). Clonal cell lines expressing the human dopamine D₄ receptor are harvested and homogenized (polytron) in a 50 mM Tris:HCl (pH 7.4 at 4 °C) buffer containing 5 mM EDTA, 1.5 mM calcium chloride (CaCl₂), 5 mM magnesium chloride (MgCl₂), 5 mM potassium chloride (KCl) and 120 mM sodium chloride (NaCl). The homogenates are centrifuged for 10-15 min. at 48,000 g, and the resulting pellets 20 resuspended in a buffer at a concentration of 150-250 mg/ml. For saturation experiments, 0.75 ml aliquots of tissue homogenate are incubated in triplicate with increasing concentrations of [³H]-spiperone (70.3 Ci/mmol; 10-3000 pM final concentration) for 30-120 minutes at 22 °C in a total volume of 1 ml. For competition binding experiments, assays are initiated by the addition of 0.75 ml of membrane and incubated in duplicate 25 with the indicated concentrations of competing ligands (10⁻¹⁴-10⁻³ M) and/or [³H]-spiperone (100-300 pM) for 60-120 min at 22°C. Assays are terminated by rapid filtration through a Brandell cell harvester and the filters subsequently monitored for tritium as described by Sunahara, R.K. et al. (*Nature*, 1990, 346, 76). For all experiments, specific [³H]spiperone binding is defined as that inhibited by 1-10 mM (+)-butaclamol. Binding data 30 are analyzed by non-linear least square curve-fitting. The compounds of the Examples were tested in this assay, and all were found to have binding affinities (K_i) for the displacement of [³H]-spiperone of less than 2 micromolar.

5

Human D4 receptor modulation of cAMP formation

Chinese hamster ovary (CHO) cells expressing the human D4.4 dopamine receptor were obtained from Dr. H. Van Tol (Clarke Institute of Psychiatry, Toronto), and were grown to confluence in Minimal Essential Alpha Media (Gibco) supplemented with 2.5% Fetal Bovine Serum (not heat inactivated), 2.5% Equine Serum (heat inactivated), and 500 µg/ml Geneticin. Monolayers were disrupted and cells dislodged with 5 mM ethylenediaminetetraacetic acid (EDTA) and resuspended in phosphate buffered saline buffer containing 5 mM magnesium chloride, 30 mM hydroxyethylpiperazine-N-ethanesulfonic acid (HEPES), 300 µM 3-isobutyl-1-methyl-xanthine (IBMX, a phosphodiesterase inhibitor), and 5.6 mM dextrose. Cells (approximately 200,000/tube) were exposed to 5 µM forskolin (an adenylate cyclase activator), forskolin plus test compounds or quinpirole (a D4 receptor agonist), or forskolin plus quinpirole plus antagonist for 11 minutes. In experiments with antagonists, cells were exposed to antagonists 11 minutes prior to agonist challenge. The effect of test compounds in the absence of the agonist quinpirole was used to judge agonist activity. D4 agonists produce an inhibition of cAMP accumulation which can be reversed by D4 receptor antagonists. The reaction was terminated with the addition of 6N perchloric acid, and samples neutralized with 5N potassium hydroxide and 2M Tris buffer. Cyclic AMP levels were measured using a commercially available competitive binding kit (Amersham). IC₅₀ values were calculated by linear regression analysis of the concentration-response curves. K_i values were calculated using the equation: K_i = IC₅₀/(1 + [agonist]/[agonist EC₅₀]) (Minneman and Johnson, 1984).

The present invention is illustrated by the following examples, but it is not limited to the details thereof.

EXAMPLE 1

30

2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole

A mixture of 5 gm of 5-fluoro 2 indole carboxylic acid, 2.74 gm of O-, N-dimethyl hydroxylamine hydrochloride, 3.89 ml triethylamine and 5.76 gm of dicyclohexylcarbodiimide in 35 ml methylene chloride is stirred at ambient temperature until a tan precipitate is formed. The solid is removed by filtration, the residue concentrated and purified on SiO₂ (25%) EtOAc in Hexane) obtained are 3.6 gm (64%) of the N-O-dimethyl 2 indole hydroxamide.

5 3.9 gm of N-O-dimethyl 2 indole hydroxylamide is added over a period of 5 minutes to a cold suspension (-40 C) of 0.67 gm LiAlH4 in 30 ml tetrahydrofuran. The mixture is stirre for an hour (-40 C-> -30 C) treated with a saturated aqueous solution of sodium sulfate and warmed to ambient temperature. The solvent is separated after addition of solid sodiumsulfate and concentrated until a solid precipitate is formed (2.94
10 gm of 5-fluoro 2-indolecarboxaldehyde.

A mixture of 0.96 gm of 4-(5-chloro-phenyl)-piperazine, 1.0 gm of 5-Fluoro, 2-indolecarboxaldehyde and 1.2 gm of sodium triacetoxyborohydride in 50 ml dichloroethane is stirred under nitrogen at ambient temperature for 48 hours. The solvent is removed and the residue portioned between 100 ml EtOAc and 20 ml NaOH
15 (1N). The organic layer is washed with water (2x20ml) and brine (1x10 ml) and concentrated. The residue is purified on SiO2 (eluent: 5% methanol in methylene chloride) to yield 1.02 gm of a cream colored solid which has a mp.: 204-205 C°).

EXAMPLE 2

5-Fluoro-1H-indol-2-yl-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone

20 A mixture of 1.0 mmol of 5-fluoro, 2-indole carboxylicacidchloride and 230 mg of meta-trifluoromethylphenylpiperazine and 129 mg of diisopropylethylamine in 10 ml methylenchloride is kept at ambient temperature for 12 hours. Water is added, the organic layers separated, washed with wate, dried over sodium sulfate and concentrated to yield 296 mg of the title compound. MP: 198°C.

EXAMPLE 3

5-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole hydrochloride

A solution of 275 mg of 5-Fluoro-1H-indol-2-yl-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]methanone in 5 ml anhydrous tetrahydrofuran is kept under an inert gas
30 atmosphere and is treated at ambient temperature with 2.11 ml of a 1M solution of Lithiumaluminumhydride in tetrahydrofuran. After 12 hours the mixture is treated with 78 μ l 15% Sodium Hydroxide solution and again 234 μ l water. After addition of magnesiumsulfate the organic layer is separated and concentrated to a yellow oil (240 mg). This oil is dissolved in ether and treated with an ether solution of hydrochloric acid
35 until a precipitate is formed. The precipitate is collected, dried under vacuum.

The title compounds of Examples 4- were prepared by a methods analogous to that described in Example 1-3.

5

EXAMPLE 42-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indol-5-ol

MP: 188-190°C; HRSMS 375.15.

10

EXAMPLE 52-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole

MP: 192-194°C; HRSMS 359.15.

15

EXAMPLE 6(1H-Indol-2-yl)-[4-(2-nitro-phenyl)-piperazin-1-yl]-methanone

MP: 186-189°C.

20

EXAMPLE 7(5-Fluoro-1H-indol-2-yl)-[4-(2-nitro-phenyl)-piperazin-1-yl]-methanone

MP: 184-188°C.

25

EXAMPLE 8(5-Fluoro-1H-indol-2-yl)-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone

MP: 198°C.

30

EXAMPLE 93-[4-(1H-Indol-2-ylmethyl)-piperazin-1-yl]-benzo[d]isothiazole

MP: 150-152°C; MRSMS 348.12.

EXAMPLE 105-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole

MP: 196-197°C; HRSMS 377.148.

EXAMPLE 112-(4-Naphthalen-1-yl-piperazin-1-ylmethyl)-1H-indole

MP: 238-239°C; HRSMS 341.19.

EXAMPLE 122-[4-(2-Nitro-phenyl)-piperazin-1-ylmethyl]-1H-indole

MP: 210-211°C; HRSMS 336.16.

EXAMPLE 135-Fluoro-2-[4-(2-nitro-phenyl)-piperazin-1-ylmethyl]-1H-indole

MP: 236°C; HRSMS 354.14.

5

EXAMPLE 145-Fluoro-2-(4-naphthalen-1-yl-piperazin-1-ylmethyl)-1H-indole

MP: 249-250°C; HRSMS 359.18.

10

MP: 242°C; HRSMS 310.15.

EXAMPLE 155-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole

MP: 242°C; HRSMS 310.15.

EXAMPLE 165-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole

MP:

EXAMPLE 17

15

5-Fluoro-2-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-1H-indole

MP: 199°C; HRSMS 311.16.

EXAMPLE 18(5-Fluoro-1H-indol-2-yl)-(4-pyridin-2-yl-piperazin-1-yl)-methanone

MP: 214-218°C.

20

EXAMPLE 192-(4-Pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole

MP:

EXAMPLE 20(1H-Indol-2-yl)-(4-pyridin-2-yl-piperazin-1-yl)-methanone

25

MP: 198-200°C.

EXAMPLE 212-(4-Pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole¹³C NMR (CDCl₃, 75 MHz) δ 45.29, 53.03, 55.96, 77.44, 101.94, 107.29, 110.91, 113.52, 119.70, 120.28, 121.69, 128.40, 135.53, 136.37, 137.61, 148.00, 30 159.55.¹H NMR (CDCl₃, 250 MHz) δ 2.6 (m, 4H), 3.6 (m, 4H), 3.7 (s, 2H), 6.4 (s, 1H), 6.7 (m, 2H), 7.1-7.6 (m, 4H), 8.2 (m, 1H), 8.7 (br. s, 1H).GC-MS, t_R = 4.468 min., M⁺ = 292, (M-162) = 130.

5

EXAMPLE 22

(2' α , 3' $\alpha\beta$, 6' $\alpha\beta$)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-1',2',3',3' α ,4',6' α -hexahydro-pentalen-2'-yl)-piperazine dihydrochloride

MP: 250-253°C. Analysis calculated for $C_{24}H_{27}FN_2 \cdot 2 HCl \cdot 0.75 H_2O$: C, 66.28; H, 7.07; N, 6.44. Found: C, 66.18; H, 6.76; N, 6.56.

10

EXAMPLE 23

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'-ol maleate

MP: 206-207.5°C. Analysis calculated for $C_{24}H_{29}FN_2O \cdot 0.75 C_4H_4O_4 \cdot 0.75 H_2O$: C, 67.41; H, 7.02; N, 5.82. Found: C, 67.24; H, 6.77; N, 5.68.

15

EXAMPLE 24

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine dihydrochloride

MP: 255-256.5°C. Analysis calculated for $C_{24}H_{29}FN_2 \cdot 2 HCl \cdot 0.25 H_2O$: C, 65.23; H, 7.18; N, 6.34. Found: C, 65.40; H, 7.02; N, 6.38.

20

EXAMPLE 25

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-hydroxy-5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile maleate

MP: 207-207.5°C. Analysis calculated for $C_{25}H_{28}FN_3O \cdot C_4H_4O_4$: C, 66.78; H, 6.18; N, 8.06. Found: C, 66.64; H, 6.06; N, 8.14.

25

EXAMPLE 26

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(3', 3' α , 4', 5', 6', 6'-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile maleate

30

MP: 221-221.5°C. Analysis calculated for $C_{26}H_{28}FN_3O \cdot C_4H_4O_4 \cdot 0.5 H_2O$: C, 66.41; H, 6.13; N, 7.74. Found: C, 66.33; H, 6.26; N, 7.61.

EXAMPLE 27

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'-ol maleate

35

MP: 188-189°C. Analysis calculated for $C_{25}H_{32}N_2O_2 \cdot C_4H_4O_4$: C, 68.48; H, 7.13; N, 5.51. Found: C, 68.64; H, 7.10; N, 5.81.

5

EXAMPLE 28

(2^α, 3^α, 5^α, 6^{αβ})-2-(4-Fluoro-phenyl)-5'-(4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-ol maleate

MP: 219.5-220°C. Analysis calculated for C₂₂H₂₆F₂N₄O₄• C₄H₄O₄•0.5 H₂O: C, 59.41; H, 5.94; N, 10.66. Found: C, 59.76; H, 5.89; N, 10.65.

10

EXAMPLE 29

(2^α, 3^α, 5^α, 6^{αβ})-2-Fluoro-4-[4-(5'-4-fluoro-phenyl)-5'-hydroxy-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 204-204.5°C. Analysis calculated for C₂₅H₂₇F₂N₃O₄• C₄H₄O₄•H₂O: C, 62.47; H, 5.97; N, 7.54. Found: C, 62.77; H, 5.74; N, 7.58.

15

EXAMPLE 30

(2^α, 3^α, 5^α, 6^{αβ})-2'-(4-Fluoro-phenyl)-5'-(4-(4-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-ol maleate

MP: 209-209.5°C. Analysis calculated for C₂₄H₂₈F₂N₂O₄• C₄H₄O₄: C, 65.36; H, 6.27; N, 5.54. Found: C, 65.65; H, 6.25; N, 5.34.

20

EXAMPLE 31

(2^α, 3^α, 6^{αβ})-5-Fluoro-2-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate

MP: 202-203°C. Analysis calculated for C₂₂H₂₅FN₄• C₄H₄O₄: C, 64.99; H, 6.08; N, 11.66. Found: C, 64.67; H, 6.00; N, 11.79.

25

EXAMPLE 32

(2^α, 3^α, 6^{αβ})-2-Fluoro-4-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile maleate

MP: 172-173°C. Analysis calculated for C₂₅H₂₆FN₃• C₄H₄O₄: C, 69.17; H, 6.00; N, 8.34. Found: C, 69.06; H, 5.88; N, 8.57.

30

EXAMPLE 33

(2^α, 3^α, 5^α, 6^{αβ})-5-Fluoro-2-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate

MP: 211.5-212°C. Analysis calculated for C₂₂H₂₇FN₄• C₄H₄O₄: C, 64.72; H, 6.48; N, 11.61. Found: C, 64.67; H, 6.43; N, 11.82.

35

5

EXAMPLE 34

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile maleate

MP: 195-196°C. Analysis calculated for $C_{25}H_{28}FN_3$ • $C_4H_4O_4$: C, 68.89; H, 6.38; N, 8.31. Found: C, 68.99; H, 6.47; N, 8.30.

10

EXAMPLE 35

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-[5'-(2-trifluoromethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 192-193°C. Analysis calculated for $C_{26}H_{27}F_4N_3$ • $C_4H_4O_4$: C, 62.82; H, 5.45; N, 7.33. Found: C, 62.87; H, 5.22; N, 7.27.

15

EXAMPLE 36

(2' α , 3' $\alpha\beta$, 6' $\alpha\beta$)-2-Fluoro-4-[4-[5-(2-methoxy-phenyl)-1'2'3'3'a,4'6'a-hexahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 155-156°C. Analysis calculated for $C_{26}H_{28}FN_3O$ • $C_4H_4O_4$ • 0.25H₂O: C, 66.96; H, 6.09; N, 7.81. Found: C, 67.00; H, 6.05; N, 7.82.

20

EXAMPLE 37

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 176-177°C. Analysis calculated for $C_{26}H_{30}FN_3O$ • $C_4H_4O_4$ • 0.50H₂O: C, 66.16; H, 6.48; N, 7.71. Found: C, 66.20; H, 6.31; N, 7.69.

25

EXAMPLE 38

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-[5'-(1H-indol-3-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 226-227°C. Analysis calculated for $C_{27}H_{29}FN_4$ • $C_4H_4O_4$: C, 68.37; H, 6.11; N, 10.29. Found: C, 68.17; H, 6.24; N, 10.20.

30

EXAMPLE 39

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-[5'-(2-methanesulfonyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 179-180°C. Analysis calculated for $C_{26}H_{30}FN_3O_2S$ • $C_4H_4O_4$ • 0.25 H₂O: C, 61.25; H, 5.91; N, 7.14. Found: C, 61.26; H, 6.32; N, 6.76.

35

5

EXAMPLE 40

(2 α , 3 α β , 5 β , 6 α β)-2-Fluoro-4-[4-(3', 3 α , 4, 4', 5', 6', 6 α -hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl]-1-piperazinyl]-benzonitrile maleate

MP >260°C. Analysis calculated for C₂₆H₂₈FN₃O₂• CH₄O₃S: C, 63.14; H, 6.27; N, 8.18. Found: C, 63.12; H, 6.66; N, 8.00.

EXAMPLE 41

(2 α , 3 α β , 5 α , 6 α β)-2-Fluoro-4-[4-(3, 3', 3 α , 4, 4', 5', 6', 6 α -hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-1-piperazinyl]-benzonitrile maleate

MP: 176-177°C. Analysis calculated for C₂₇H₂₈FN₃O₂• C₄H₄O₄•0.50 H₂O: C, 65.25; H, 5.82; N, 7.36. Found: C, 65.52; H, 6.06; N, 7.19.

EXAMPLE 42

(2 α , 3 α β , 5 β , 6 α β)-2-Fluoro-4-[4-(3, 3', 3 α , 4, 4', 5', 6', 6 α -hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-1-piperazinyl]-benzonitrile maleate

MP: 179-180°C. Analysis calculated for C₂₇H₂₈FN₃O₂• C₄H₄O₄: C, 66.30; H, 5.74; N, 7.48. Found: C, 66.17; H, 6.07; N, 7.34.

EXAMPLE 43

(2 α , 3 α β , 5 α , 6 α β)-2-Fluoro-4-[4-(5'-(2-trifluoromethoxy-phenyl)-octahydro-pentalen-2'-yl]-1-piperazinyl]-benzonitrile maleate

MP: 126-129°C. NMR DMSO d₆ δ 7.70 (t, J=8.5 Hz, 1H), 7.52 (d, J=7.1 Hz, 1H), 7.40-7.25 (m, 3H), 7.09 (d, J=13.6 Hz, 1H), 6.96 (d, J=9.0 Hz, 1H), 6.06 (s, 2H), 3.73-2.90 (br m, 10H), 2.65-2.54 (m, partially under DMSO, 1H), 2.46-2.18 (m, 4H), 1.63-1.42 (m, 4H).

EXAMPLE 44

(2 α , 3 α β , 5 α , 6 α β)-2-Fluoro-4-[4-(5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-1-piperazinyl]-benzonitrile maleate

MP: 179-180.5°C. Analysis calculated for C₂₅H₂₇F₂N₃• C₄H₄O₄: C, 66.53; H, 5.97; N, 8.03. Found: C, 66.62; H, 6.24; N, 7.98.

5

EXAMPLE 45

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Cyano-4-[4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 193-194°C. Analysis calculated for $C_{26}H_{27}FN_4$ • $C_4H_4O_4$ •0.50 H_2O : C, 66.78; H, 5.98; N, 10.38. Found: C, 66.99; H, 6.05; N, 10.34.

10

EXAMPLE 46

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-[5'-pyridin-2-yl-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile dihydrochloride

MP: 203-206°C. Analysis calculated for $C_{24}H_{27}FN_4$ • 2HCl• H_2O : C, 59.88; H, 6.49; N, 11.63. Found: C, 59.55; H, 6.42; N, 11.47.

15

EXAMPLE 47

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-pyrimidine maleate

MP: 183.5-184.5°C. Analysis calculated for $C_{23}H_{29}FN_4O$ • $C_4H_4O_4$: C, 63.26; H, 6.49; N, 10.93. Found: C, 63.21; H, 6.71; N, 10.82.

20

EXAMPLE 48

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-[5'-(6-fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile dimesylate

MP: 219-222°C. Analysis calculated for $C_{26}H_{27}FN_5O$ • 2CH₄O₃S: C, 51.29; H, 5.38; N, 10.68. Found: C, 51.84; H, 5.57; N, 10.64.

25

EXAMPLE 49

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-2-Fluoro-4-[4-[5'-(6-fluoro-2-methylbenzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile dimesylate

MP: >260°C. Analysis calculated for $C_{27}H_{29}F_2N_5$ • 2CH₄O₃S•0.50 H_2O : C, 52.56; H, 5.48; N, 10.57. Found: C, 52.64; H, 5.71; N, 10.57.

30

EXAMPLE 50

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-(3', 3' α , 4', 5', 6', 6'-hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5-yl)-piperazin-1-yl]-pyrimidine

MP = 186°C. NMR CDCl₃ δ 8.20 (s, 2H), 7.25-7.17 (m, 4H), 7.12-7.09 (m, 1H), 5.00 (s, 2H), 3.79-3.71 (m, 4H), 2.72-2.44 (m, 7H), 2.20-2.13 (m, 2H), 2.17-1.93 (m, 2H), 1.69-1.67 (s, 2H).

35

5

EXAMPLE 51

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-5-Fluoro-2-[4-(3', 3' α , 4', 4', 5', 6', 6' α -hexahydrospiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl]-piperazin-1-yl]-pyrimidine

MP: 186-187°C. NMR CDCl₃ δ 8.18 (s, 2H), 7.26-7.10 (m, 3H), 7.08-7.06 (m, 1H), 5.00 (s, 2H), 3.78-3.76 (br s, 4H), 2.78-2.73 (m, 2H), 2.66-2.54 (m, 5H), 2.32-10 2.22 (m, 4H), 1.74-1.69 (m, 2H), 1.38-1.29 (m, 2H).

EXAMPLE 52

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-1-Phenyl-4-(3', 3' α , 4, 4', 5', 6', 6' α -hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-5'-yl)-piperazine maleate

MP: 200-201°C. Analysis calculated for C₂₆H₃₀N₂O₂• C₄H₄O₄: C, 69.48; H, 6.61; 15 N, 5.40. Found: C, 69.48; H, 6.80; N, 5.44.

EXAMPLE 53

(2' β , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-1-Phenyl-4-(3', 3' α , 4, 4', 5', 6', 6' α -hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-5'-yl)-piperazine maleate

MP: 220-221°C. Analysis calculated for C₂₆H₃₀N₂O₂• C₄H₄O₄: C, 69.48; H, 6.61; 20 N, 5.40. Found: C, 69.28; H, 6.84; N, 5.33.

EXAMPLE 54

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-3-[5'-(4-Phenyl-piperazin-1-yl)- octahydro-pentalen-2'-yl]-1H-indole maleate

MP: 232-232.5°C. Analysis calculated for C₂₆H₃₁N₃• C₄H₄O₄: C, 71.83; H, 7.03; 25 N, 8.38. Found: C, 71.57; H, 7.38; N, 8.31.

EXAMPLE 55

(2' α , 3' $\alpha\beta$, 6' $\alpha\beta$)-1-Phenyl-4-(5'-phenyl-1',2',3',3' α ,4',6' α -hexahydro-pentalen-2'-yl)-piperazine dimaleate

MP: 156-157°C. Analysis calculated for C₂₆H₃₀N₂O₂•2C₄H₄O₄: C, 66.65; H, 30 6.29; N, 4.86. Found: C, 66.27; H, 6.57; N, 5.00.

EXAMPLE 56

(2' α , 3' $\alpha\beta$, 5' α , 6' $\alpha\beta$)-1-Phenyl-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine maleate

MP: 217-218°C. Analysis calculated for C₂₄H₃₀N₂• C₄H₄O₄: C, 72.70; H, 7.41; 35 N, 6.06. Found: C, 72.28; H, 7.46; N, 6.01.

5

EXAMPLE 57

(2 α , 3 α β , 5 α , 6 α β)-6-Fluoro-2-methyl-1-[5'-(4-phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-benzoimidazole dimaleate

MP: 203-205°C. Analysis calculated for $C_{26}H_{31}FN_4$ • $2C_4H_4O_4$ • 0.50 H₂O: C, 61.90; H, 6.11; N, 8.49. Found: C, 61.96; H, 6.01; N, 8.58.

10

EXAMPLE 58

(2 α , 3 α β , 5 β , 6 α β)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine maleate

MP: 177-178°C. Analysis calculated for $C_{24}H_{29}FN_2O$ • $C_4H_4O_4$: C, 67.72; H, 6.70; N, 5.64. Found: C, 67.33; H, 6.82; N, 5.62.

15

EXAMPLE 59

(2 α , 3 α β , 5 β , 6 α β)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate

MP: 235.5-236°C. Analysis calculated for $C_{26}H_{29}N_3O_2$ • $C_4H_4O_4$: C, 67.78; H, 6.26; N, 7.90. Found: C, 67.71; H, 6.37; N, 7.94.

20

EXAMPLE 60

(2 α , 3 α β , 5 α , 6 α β)-N-(2-[5'-4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl)-phenyl)-acetamide maleate

MP: 211.5-212°C. Analysis calculated for $C_{24}H_{30}FN_5O$ • $C_4H_4O_4$: C, 62.33; H, 6.35; N, 12.98. Found: C, 62.07; H, 6.32; N, 12.87.

25

EXAMPLE 61

(2 α , 3 α β , 5 α , 6 α β)-N-(2-[5'-4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl)-phenyl)-acetamide maleate

MP: 197-199°C. Analysis calculated for $C_{27}H_{31}FN_4O$ • $C_4H_4O_4$: C, 66.18; H, 6.27; N, 9.96. Found: C, 66.06; H, 6.20; N, 9.89.

30

EXAMPLE 62

(2 α , 3 α β , 5 α , 6 α β)-2-Fluoro-4-[4-[5'-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile mesylate

MP >260°C. Analysis calculated for $C_{26}H_{28}FN_5O$ • CH_4O_3S • 0.50 H₂O: C, 58.89; H, 6.04; N, 12.72. Found: C, 59.01; H, 6.06; N, 12.71.

35

5

EXAMPLE 63

(2' α , 3' α β , 5' α , 6' α β)-1-[5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-1,3-dihydro-benzimidazol-2-one mesylate

MP >260°C. Analysis calculated for $C_{23}H_{27}FN_6O\bullet CH_4O_3S$: C, 55.58; H, 6.04; N, 16.20. Found: C, 55.48; H, 5.87; N, 16.41.

10

EXAMPLE 64

(2' α , 3' α β , 5' α , 6' α β)-2-[5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-benzamide maleate

MP 198.5-200°C. Analysis calculated for $C_{26}H_{29}FN_4O\bullet C_4H_4O_4\bullet 0.50 H_2O$: C, 64.62; H, 6.15; N, 10.05. Found: C, 64.84; H, 6.01; N, 10.03.

15

EXAMPLE 65

(2' α , 3' α β , 5' α , 6' α β)-N-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-benzamide maleate

MP: 211-212.5°C. Analysis calculated for $C_{25}H_{31}N_3O\bullet C_4H_4O_4\bullet 0.25 H_2O$: C, 68.28; H, 7.01; N, 8.23. Found: C, 68.17; H, 6.94; N, 8.18.

20

EXAMPLE 66

(2' α , 3' α β , 5' β , 6' α β)-2-Fluoro-4-[4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 192-193°C. Analysis calculated for $C_{25}H_{27}F_2N_3O\bullet C_4H_4O_4$: C, 64.55; H, 5.79; N, 7.79. Found: C, 64.50; H, 5.80; N, 7.71.

25

EXAMPLE 67

(2' α , 3' α β , 5' β , 6' α β)-5-Fluoro-2-[4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-pyrimidine maleate

MP: 192-194°C. Analysis calculated for $C_{22}H_{26}F_2N_4O\bullet C_4H_4O_4$: C, 60.46; H, 5.85; N, 10.85. Found: C, 60.30; H, 5.82; N, 10.78.

30

EXAMPLE 68

(2' α , 3' α β , 5' β , 6' α β)-2-Fluoro-4-[4-[5'-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 170-177°C. NMR DMSO d_6 δ 10.89 (s, 1H), 7.70 (t, $J=8.4$ Hz, 1H), 7.30-7.23 (m, 1H), 7.11 (d, $J=13.9$ Hz, 1H), 7.04-6.94 (m, 4H), 6.06 (s, 2H), 4.97-4.82 (m, 1H), 3.62-2.80 (br m, 10H), 2.75-2.63 (m, 2H), 2.60-2.50 (m partially under DMSO peak, 1H), 2.48-2.36 (m, 2H), 1.60 (dd, $J_1=12.4$ Hz, $J_2=6.6$ Hz, 2H), 1.58-1.34 (m, 2H).

5

EXAMPLE 69

(2^α, 3^α, 5^α, 6^{αβ})-2-Fluoro-4-[4-[5'-(3-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 169-170°C. Analysis calculated for C₂₆H₃₀FN₃O₂ C₄H₄O₄: C, 67.27; H, 6.40; N, 7.85. Found: C, 67.18; H, 6.52; N, 7.87.

10

EXAMPLE 70

(2^α, 3^{αβ}, 5^α, 6^{αβ})-2-Fluoro-4-[4-[5'-(4-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile maleate

MP: 186-186.5°C. Analysis calculated for C₂₆H₃₀FN₃O₂ C₄H₄O₄•0.25 H₂O: C, 66.71; H, 6.44; N, 7.78. Found: C, 66.70; H, 6.60; N, 7.60.

15

EXAMPLE 71

(2^α, 3^{αβ}, 5^α, 6^{αβ})-2-Fluoro-4-[4-(5'-m-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile maleate

MP: 198-198.5°C. Analysis calculated for C₂₆H₃₀FN₃O₂ C₄H₄O₄: C, 69.35; H, 6.60; N, 8.09. Found: C, 69.48; H, 6.74; N, 8.14.

20

EXAMPLE 72

(2^α, 3^{αβ}, 5^α, 6^{αβ})-2-Fluoro-4-[4-(5'-p-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile maleate

MP: 194-195°C. NMR DMSO d₆ δ 7.70 (t, J=8.5Hz, 1H), 7.16-7.09 (m, 5H), 6.96 (d, J=8.7Hz, 1H), 6.06 (s, 2H), 3.75-2.85 (m, 11H), 2.55-2.43 (m partially under 25 DMSO peak, 1H), 2.40-2.23 (m with singlet @ 2.26, 7H total), 1.63-1.32 (m, 4H).

EXAMPLE 73

(2^β, 3^{αβ}, 5^β, 6^{αβ})-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine maleate

MP: 174-175°C. Analysis calculated for C₂₄H₂₉FN₃O₂ C₄H₄O₄: C, 67.72; H, 6.70; N, 5.64. Found: C, 67.82; H, 6.83; N, 5.59.

EXAMPLE 74

(2^α, 3^{αβ}, 5^α, 6^{αβ})-2-Fluoro-4-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile maleate

MP: 198-199°C. Analysis calculated for C₂₆H₃₀FN₃O₂ C₄H₄O₄: C, 69.35; H, 6.60; N, 8.09. Found: C, 69.13; H, 6.69; N, 8.12.

5

EXAMPLE 75

(2'a, 3'aβ, 5'a, 6'aβ)-1-Phenyl-4-[5'-(3-pyrrolidin-1-ylmethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazine dimaleate

MP: 163.5-164°C. Analysis calculated for $C_{29}H_{39}N_3O \cdot 2C_4H_4O_4$: C, 67.15; H, 7.16; N, 6.35. Found: C, 66.81; H, 7.22; N, 6.27.

10

EXAMPLE 76

(2'a, 3'aβ, 5'a, 6'aβ)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro(isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine maleate

MP: 224.5-225°C. Analysis calculated for $C_{25}H_{31}FN_4O \cdot C_4H_4O_4 \cdot 0.25 H_2O$: C, 64.13; H, 6.59; N, 10.32. Found: C, 64.25; H, 6.68; N, 10.14.

20

EXAMPLE 77

(2'B, 3'aβ, 5'a, 6'aβ)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro(isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine maleate

MP: 222-223°C. NMR DMSO d_6 δ 8.58 (s, 2H), 7.34-7.30 (m, 1H), 7.28-7.25 (m, 3H), 6.04 (s, 2H), 4.94 (s, 2H), 3.65-2.75 (br m, 9H), 2.20-2.12 (m, 2H), 1.94 (AB quartet, $\Delta \nu = 37.8\text{Hz}$, $J=13.2\text{Hz}$, 4H), 1.54 (br t, $J=11.7\text{Hz}$, 2H), 1.21 (s, 6H).

25

EXAMPLE 78

(2'a, 3'aβ, 5'b, 6'aβ)-4-(4-[5'-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl)-2-fluoro-benzonitrile maleate

MP: 224-224.5°C. Analysis calculated for $C_{27}H_{27}FN_4O_2 \cdot C_4H_4O_4$: C, 64.80; H, 5.44; N, 9.75. Found: C, 64.85; H, 5.56; N, 9.74.

30

EXAMPLE 79

(2'a, 3'aβ, 5'b, 6'aβ)-2-[5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate

MP: 241.5-242°C. Analysis calculated for $C_{24}H_{26}FN_5O_2 \cdot C_4H_4O_4$: C, 60.97; H, 5.48; N, 12.70. Found: C, 60.66; H, 5.55; N, 12.44.

5

EXAMPLE 80

(2 α , 3 α β , 5 α , 6 α β)-2-Fluoro-4-[4-(3, 3', 3 α , 4, 4', 5', 6', 6 α -hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-5'-yl]-1-piperazinyl]-benzonitrile maleate

MP: 219-220°C. Analysis calculated for $C_{24}H_{26}F_2N_4O_2$ • $C_4H_4O_4$ • 0.50 H_2O : C, 59.46; H, 5.55; N, 9.90. Found: C, 59.86; H, 5.70; N, 9.40.

10

EXAMPLE 81

(2 β , 3 α β , 5 α , 6 α β)-2-Fluoro-4-[4-(3, 3', 3 α , 4, 4', 5', 6', 6 α -hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl]-5'-yl]-1-piperazinyl]-benzonitrile maleate

MP: 216.5-217°C. Analysis calculated for $C_{24}H_{26}F_2N_4O_2$ • $C_4H_4O_4$: C, 60.43; H, 5.43; N, 10.07. Found: C, 60.39; H, 5.47; N, 9.90.

15

EXAMPLE 82

(2 α , 3 α β , 5 α , 6 α β)-5-Fluoro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate

MP: 204-205°C. Analysis calculated for $C_{23}H_{29}FN_4$ • $C_4H_4O_4$: C, 65.31; H, 6.70; N, 11.28. Found: C, 65.38; H, 6.77; N, 11.32.

20

EXAMPLE 83

(2 β , 3 α β , 5 α , 6 α β)-1-(5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl)-1,3-dihydro-benzimidazol-2-one maleate

MP: 217-218°C. Analysis calculated for $C_{25}H_{29}FN_4O$ • $C_4H_4O_4$: C, 64.91; H, 6.20; N, 10.44. Found: C, 64.57; H, 6.28; N, 10.18.

25

EXAMPLE 84

(2 β , 3 α β , 5 α , 6 α β)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yloxy]-1H-benzimidazole maleate

MP: 161-162°C. Analysis calculated for $C_{25}H_{30}N_4O$ • $C_4H_4O_4$: C, 67.16; H, 6.61; N, 10.80. Found: C, 67.05; H, 6.66; N, 10.59.

30

EXAMPLE 85

(2 α , 3 α β , 5 α , 6 α β)-5-Chloro-2-[4-(5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate

MP: 199.5-200°C. Analysis calculated for $C_{23}H_{29}ClN_4O$ • $C_4H_4O_4$: C, 61.30; H, 6.29; N, 10.59. Found: C, 61.05; H, 6.31; N, 10.83.

35

5

EXAMPLE 86

(2' α , 3' α β , 5' α , 6' α β)-5-Chloro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate

MP: 200-200.5°C. Analysis calculated for $C_{23}H_{29}ClN_4$ • $C_4H_4O_4$: C, 63.21; H, 6.48; N, 10.92. Found: C, 62.97; H, 6.33; N, 11.29.

10

EXAMPLE 87

(2' β , 3' α β , 5' α , 6' α β)-2-[5'-[4-(3,4-Difluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate

MP: 221.5-222°C. Analysis calculated for $C_{26}H_{27}F_2N_3O_2$ • $C_4H_4O_4$: C, 63.48; H, 5.51; N, 7.46. Found: C, 63.28; H, 5.51; N, 7.64.

15

EXAMPLE 88

(2' β , 3' α β , 5' α , 6' α β)-2-[5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate

MP: 209-210°C. Analysis calculated for $C_{26}H_{28}FN_3O_2$ • $C_4H_4O_4$ • 0.50H₂O: C, 64.51; H, 5.95; N, 7.52. Found: C, 64.47; H, 5.91; N, 7.66.

20

EXAMPLE 89

(2' β , 3' α β , 5' α , 6' α β)-1-[5'-[4-(3,4-Difluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-1,3-dihydro-benzimidazol-2-one maleate


MP: 201-202°C. Analysis calculated for $C_{25}H_{26}F_2N_4O$ • $C_4H_4O_4$ • 0.50H₂O: C, 61.80; H, 5.90; N, 9.94. Found: C, 62.10; H, 5.80; N, 9.56.

25

5

Claims

1. A compound of the formula



or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

10 a is 0 or 1, wherein when a is 0, X may form an optional double bond with the carbon adjacent to V;

V is CHR^{10} wherein R^{10} is hydrogen or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;

T is nitrogen or CH ;

15 X is nitrogen or CR^{11} wherein R^{11} is hydrogen, $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$, hydroxy or cyano;

Y and Z are each independently nitrogen or CR^{12} wherein R^{12} is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$ or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;


R^1 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;

20 R^2 , R^6 , R^7 , R^8 and R^9 are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$ and $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$;

R^3 and R^4 are each independently hydrogen or $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$; and

R^5 is hydrogen, $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$, trifluoromethyl, cyano, $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$ or $\text{R}^{13}\text{CO-}$ wherein R^{13} is amino, $(\text{C}_1\text{-}\text{C}_6)\text{alkylamino}$, $((\text{C}_1\text{-}\text{C}_6)\text{alkyl})_2\text{amino}$, $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$;

25 or when a is 1, R^1 and R^{10} may be taken together with the carbons to which they are attached to form a compound of the formula



wherein the broken lines represent optional bonds;

T, X, Y, Z, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are defined as above;

b is 0 or 1; and

A and B are each independently CH, CH₂, oxygen, sulfur, NH or nitrogen;

10 with the proviso that when X is nitrogen, the optional double bond between X and V does not exist;

with the proviso that when b is 0, the optional double bond between A and B does not exist; and

with the proviso that when b is 1; A and B cannot both be oxygen or sulfur.

15 2. A compound according to claim 1, wherein X is nitrogen.

3. A compound according to claim 1, wherein Y and Z are each CR¹² wherein R¹² is hydrogen or fluoro.

4. A compound according to claim 1, wherein R² is hydrogen, fluoro or chloro.

20 5. A compound according to claim 1, wherein R³, R⁴ and R⁵ are hydrogen.

6. A compound according to claim 1, wherein R⁷ is fluoro or chloro.

7. A compound according to claim 1, wherein R⁹ is fluoro, chloro, bromo or alkoxy.

8. A compound according to claim 1, wherein X is nitrogen; Y and Z are each CR¹² wherein R¹² is hydrogen or fluoro; R² is hydrogen, fluoro or chloro; R³, R⁴ and R⁵ are hydrogen; R⁷ is fluoro or chloro; and R⁹ is fluoro, chloro, bromo or alkoxy.

25 9. A compound according to claim 1, wherein said compound is selected from the group consisting of :

2-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;

30 5-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;

5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;

5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;

5 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;
5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole;
5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole; and
10 2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-azaindole.

10. A method for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

15. 11. A method according to claim 10, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders, ocular disorders and sleep disorders.

20. 12. A method for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to claim 1, or a pharmaceutically acceptable salt thereof, in conjunction with one or more D1, D2, D3 or D5 dopamine receptor agonists, that is effective in treating such disorder.

25. 13. A method according to claim 12, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders, ocular disorders and sleep disorders.

30. 14. A method according to claim 11, wherein psychotic disorders include affective psychosis, schizophrenia, and schizoaffective disorders.

35. 15. A method according to claim 11, wherein movement disorders include extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease.

16. A method according to claim 11, wherein gastrointestinal disorders include gastric acid secretion or emesis.

17. A method according to claim 11, wherein vascular and cardiovascular disorders include congestive heart failure and hypertension.

5 18. A pharmaceutical composition for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

10 19. A pharmaceutical composition according to claim 18, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders, ocular disorders and sleep disorders.

15 20. A pharmaceutical composition for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to claim 1, or a pharmaceutically acceptable salt thereof, in conjunction with one or more D1, D2, D3 or D5 dopamine receptor agonists, that is effective in treating such disorder.

20 21. A pharmaceutical composition according to claim 20, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders, ocular disorders and sleep disorders.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 403/12, 403/14		A3	(11) International Publication Number: WO 99/09025 (43) International Publication Date: 25 February 1999 (25.02.99)		
(21) International Application Number: PCT/IB98/01198		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).			
(22) International Filing Date: 5 August 1998 (05.08.98)					
(30) Priority Data: 60/055,764 15 August 1997 (15.08.97) US					
(71) Applicant (<i>for all designated States except US</i>): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).					
(72) Inventors; and		Published			
(75) Inventors/Applicants (<i>for US only</i>): FLIRI, Anton, Franz, Josef [AT/US]; 120 MacKinley Avenue, Norwich, CT 06360-27 (US). MAJCHRZAK, Mark, Jerome [US/US]; 10 Bobwhite Lane, East Lyme, CT 06333 (US). SEYMOUR, Patricia, Ann [US/US]; 23 Broadview Avenue, Uncasville, CT 06382 (US). ZORN, Stevin, Howard [US/US]; P.O. Box 421, North Stonington, CT 06359 (US). ROLLEMA, Hans [NL/US]; 20 Holdridge Court, Mystic, CT 06355 (US).		With international search report.			
(74) Agents: SPIEGEL, Allen, J.; c/o Simpson, Alison, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB) et al.		(88) Date of publication of the international search report: 15 April 1999 (15.04.99)			
(54) Title: 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVES INTERACTING WITH THE DOPAMINE D4 RECEPTOR					
<p style="text-align: center;">(I)</p>					
<p>(57) Abstract</p> <p>2-(4-Aryl or Heteroaryl-piperazin-1-ylmethyl)-1H-Indole derivatives of formula (I) wherein a, T, V, X, Y, Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined above, their pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds or their salts interacting with the dopamine D4 receptor.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Iceland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01198

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D403/12 C07D403/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 24105 A (MERCK SHARP & DOHME ; KULAGOWSKI JANUSZ JOZEF (GB); LEESON PAUL DAV) 27 October 1994 see the whole document ---	1-9, 18-21
X	US 3 188 313 A (ARCHER,S.) 8 June 1965 see the whole document ---	1-9, 18-21
X	EP 0 548 798 A (SANWA KAGAKU KENKYUSHO CO) 30 June 1993 see the whole document ---	1-9, 18-21
X	WO 93 01181 A (UPJOHN CO) 21 January 1993 see the whole document ---	1-8, 18-21
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
1 February 1999	10.02.99
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patenttaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax. (+31-70) 340-3018	Authorized officer Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01198

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 18628 A (UPJOHN CO ;ROMERO DONNA L (US); THOMAS RICHARD C (US); MAY PAUL D) 20 June 1996 see the whole document	1-9, 18-21
Y	WO 94 21627 A (MERCK SHARP & DOHME ;BAKER RAYMOND (GB); BROUGHTON HOWARD BARFF (G) 29 September 1994 see the whole document	1-9, 18-21
Y	EP 0 683 166 A (MERCK PATENT GMBH) 22 November 1995 see the whole document	1-9, 18-21
P,Y	WO 97 43279 A (BOSMANS JEAN PAUL R ;LOMMEN GUY ROSALIA EUGENE VAN (BE); LOVE CH) 20 November 1997 see the whole document	1-9, 18-21
A	WO 94 10162 A (MERCK SHARP & DOHME ;LEESON PAUL DAVID (GB); ROWLEY MICHAEL (GB) 11 May 1994 see the whole document	1-9, 18-21
A	WO 94 21628 A (MERCK SHARP & DOHME ;BROUGHTON HOWARD BARFF (GB); KULAGOWSKI JANUS) 29 September 1994 see the whole document	1-9, 18-21
A	WO 97 19089 A (UPJOHN CO ;THOMAS RICHARD C (US); CLEEK GARY J (US); HUTCHINSON DO) 29 May 1997 see the whole document	1-9, 18-21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 98/01198

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10 - 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/ composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 5.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-9,18-21

Indol-piperazin/piperidin-1-yl-methyl derivatives (formula I in claim 1 and claims 2-9 and 18-21 partially, examples 1-21)

2. Claims: 1-9,18-21

Tricyclic-indole derivatives (formula II in claim 1 and claims 2-9 and 18-21 partially, examples 22 - 89)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 98/01198

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9424105	A 27-10-1994	AU 6435594 A US 5814644 A		08-11-1994 29-09-1998
US 3188313	A 08-06-1965	DE 1445151 A GB 944443 A SE 342627 B		09-01-1969 14-02-1972
EP 0548798	A 30-06-1993	JP 5255089 A		05-10-1993
WO 9301181	A 21-01-1993	AT 148464 T AU 653855 B AU 2293492 A CA 2109934 A DE 69217224 D DE 69217224 T DK 594702 T EP 0594702 A ES 2097341 T GR 3023040 T JP 6509098 T US 5599930 A US 5686610 A		15-02-1997 13-10-1994 11-02-1993 21-01-1993 13-03-1997 05-06-1997 21-07-1997 04-05-1994 01-04-1997 30-07-1997 13-10-1994 04-02-1997 11-11-1997
WO 9618628	A 20-06-1996	AU 4151696 A EP 0797576 A JP 10510530 T		03-07-1996 01-10-1997 13-10-1998
WO 9421627	A 29-09-1994	AU 6215594 A US 5576336 A		11-10-1994 19-11-1996
EP 0683166	A 22-11-1995	DE 4414113 A AT 172730 T AU 697749 B AU 1648895 A CA 2147451 A CN 1114651 A CZ 9501035 A DE 59504032 D HU 74096 A JP 7291969 A NO 951529 A PL 308287 A SK 50895 A US 5693655 A ZA 9503260 A		26-10-1995 15-11-1998 15-10-1998 02-11-1995 23-10-1995 10-01-1996 13-12-1995 03-12-1998 28-11-1996 07-11-1995 23-10-1995 30-10-1995 08-11-1995 02-12-1997 09-01-1996
WO 9743279	A 20-11-1997	AU 2956197 A		05-12-1997
WO 9410162	A 11-05-1994	AU 5341394 A CA 2146018 A EP 0665840 A JP 8502958 T US 5670522 A		24-05-1994 11-05-1994 09-08-1995 02-04-1996 23-09-1997
WO 9421628	A 29-09-1994	AU 6215794 A US 5641787 A		11-10-1994 24-06-1997
WO 9719089	A 29-05-1997	AU 7665196 A		11-06-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IB 98/01198

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9719089 A		EP 0874852 A	04-11-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.